Keros Therapeutics (KROS) Receivables (2021 - 2025)
Historic Receivables for Keros Therapeutics (KROS) over the last 4 years, with Q3 2025 value amounting to $3.5 million.
- Keros Therapeutics' Receivables rose 80000.0% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year increase of 80000.0%. This contributed to the annual value of $2.7 million for FY2024, which is 181748.25% up from last year.
- According to the latest figures from Q3 2025, Keros Therapeutics' Receivables is $3.5 million, which was up 80000.0% from $15.8 million recorded in Q2 2025.
- Over the past 5 years, Keros Therapeutics' Receivables peaked at $18.0 million during Q4 2021, and registered a low of $4000.0 during Q2 2024.
- Its 4-year average for Receivables is $5.8 million, with a median of $1.6 million in 2024.
- Examining YoY changes over the last 5 years, Keros Therapeutics' Receivables showed a top increase of 39530000.0% in 2025 and a maximum decrease of 80000.0% in 2025.
- Keros Therapeutics' Receivables (Quarter) stood at $18.0 million in 2021, then tumbled by 99.21% to $143000.0 in 2023, then soared by 1817.48% to $2.7 million in 2024, then increased by 27.35% to $3.5 million in 2025.
- Its last three reported values are $3.5 million in Q3 2025, $15.8 million for Q2 2025, and $17.3 million during Q1 2025.